S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% BITCOIN 64,657.98 -0.21%
Next Bullish Trade
Sign in
UTHR

United Therapeutics Corporation NMS · UTHR

$535.67 +6.62 (+1.25%)
Pullback · -0.56σ Grade C
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · UTHR

Momentum reads · latest daily bar
Last
$535.67
+6.62 (+1.25%)
Mkt cap
$22.7B
Healthcare
RSI(14)
44.3
neutral
Stochastic %K
27.8
neutral
MFI(14)
55.8
neutral
ADX(14)
18.4
weak trend

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.8B $0.3B $0.3B $0.4B 35.2% 41.7%
2025-12-31 $0.8B $0.4B $0.4B $0.2B 46.1% 45.2%
2025-09-30 $0.8B $0.3B $0.4B $0.3B 42.4% 48.7%
2025-06-30 $0.8B $0.3B $0.4B $0.1B 38.8% 48.4%
2025-03-31 $0.8B $0.3B $0.4B $0.4B 40.6% 48.2%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare UTHR vs peers

Line UTHR up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing UTHR no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with UTHR

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-06 5.82 6.86 -15.1% -4.6%
2026-02-25 7.70 6.76 +14.0% -5.9%
2025-10-29 7.16 6.96 +2.9% -0.4%
2025-07-30 6.41 7.30 -12.2% -2.6%
2025-04-30 6.63 6.54 +1.3% -3.0%
2025-02-26 6.19 6.84 -9.5% +1.5%
2024-10-30 7.07 7.12 -0.7% +3.5%
2024-07-31 5.85 6.41 -8.7% +4.6%
2024-05-01 6.17 5.59 +10.3% +1.2%
2024-02-21 4.36 4.19 +4.2% -0.7%
2023-11-01 5.38 5.04 +6.7% +1.8%
2023-08-02 5.24 4.78 +9.5% -3.7%
2023-05-03 4.86 4.71 +3.2% -1.2%
2023-02-22 3.64 5.21 -30.0% +1.9%
2022-11-02 4.91 3.77 +30.2% +4.6%
2022-08-03 3.46 4.54 -23.8% -3.1%
2022-05-04 5.03 3.07 +63.8% +0.3%
2022-02-24 3.51 4.05 -13.3% +0.2%
2021-11-03 3.42 3.58 -4.5% -0.9%
2021-08-04 4.09 3.56 +14.7% -0.3%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
UTHR ★ $23B 19.8 16.2 7.2 13.3 3.8 86.6% -1.6% -12.2% 2.49%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 49.02%

HolderShares% out
Blackrock Inc. 5,399,649 12.72%
Avoro Capital Advisors LLC 2,630,000 6.20%
Wellington Management Group, LLP 2,264,247 5.33%
Vanguard Portfolio Management LLC 2,003,742 4.72%
Vanguard Capital Management LLC 1,957,539 4.61%
State Street Corporation 1,843,963 4.34%
Renaissance Technologies, LLC 1,787,019 4.21%
Geode Capital Management, LLC 1,233,029 2.90%
Janus Henderson Group PLC 866,930 2.04%
AQR Capital Management, LLC 826,226 1.95%

Insider activity · 90d

0 buys / 12 sells · ratio 0.0 · Finnhub

  • ROTHBLATT MARTINE A M 11,218
  • ROTHBLATT MARTINE A SELL 40,513 @ $542.80
  • ROTHBLATT MARTINE A SELL 40,553 @ $541.10
  • ROTHBLATT MARTINE A SELL 40,913 @ $539.60
  • ROTHBLATT MARTINE A SELL 41,233 @ $538.60
  • ROTHBLATT MARTINE A SELL 41,642 @ $537.66
  • ROTHBLATT MARTINE A SELL 42,307 @ $536.52
  • ROTHBLATT MARTINE A SELL 44,530 @ $535.47
  • ROTHBLATT MARTINE A SELL 46,721 @ $534.63
  • ROTHBLATT MARTINE A SELL 48,993 @ $533.70

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$516.0
Mean
$663.46155
High
$750.0
Analysts
13
Recommendation distribution · period 2026-07-01
6
12
4
Revision trend (2026-04-01 → 2026-07-01): net 16 → 18 +2 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-17 PRIMARY DOCUMENT view ·
4 2026-07-16 PRIMARY DOCUMENT view ·
4 2026-07-16 PRIMARY DOCUMENT view ·
4 2026-07-15 PRIMARY DOCUMENT view ·
4 2026-07-14 PRIMARY DOCUMENT view ·
4 2026-07-13 PRIMARY DOCUMENT view ·
4 2026-07-13 PRIMARY DOCUMENT view ·
4 2026-07-13 PRIMARY DOCUMENT view ·
4 2026-07-13 PRIMARY DOCUMENT view ·
4 2026-07-13 PRIMARY DOCUMENT view ·
4 2026-07-13 PRIMARY DOCUMENT view ·
4 2026-07-13 PRIMARY DOCUMENT view ·
4 2026-07-10 PRIMARY DOCUMENT view ·
4 2026-07-09 PRIMARY DOCUMENT view ·
4 2026-07-09 PRIMARY DOCUMENT view ·
4 2026-07-08 PRIMARY DOCUMENT view ·
4 2026-07-07 PRIMARY DOCUMENT view ·
4 2026-07-02 PRIMARY DOCUMENT view ·
4 2026-07-02 PRIMARY DOCUMENT view ·
4 2026-07-02 PRIMARY DOCUMENT view ·
4 2026-07-01 PRIMARY DOCUMENT view ·
4 2026-06-30 PRIMARY DOCUMENT view ·
4 2026-06-29 PRIMARY DOCUMENT view ·
8-K 2026-06-29 FORM 8-K view ·
4 2026-06-26 PRIMARY DOCUMENT view ·
4 2026-06-25 PRIMARY DOCUMENT view ·
4 2026-06-24 PRIMARY DOCUMENT view ·
4 2026-06-24 PRIMARY DOCUMENT view ·
4 2026-06-23 PRIMARY DOCUMENT view ·
4 2026-06-22 PRIMARY DOCUMENT view ·
4 2026-06-22 PRIMARY DOCUMENT view ·
4 2026-06-18 PRIMARY DOCUMENT view ·
4 2026-06-18 PRIMARY DOCUMENT view ·
4 2026-06-17 PRIMARY DOCUMENT view ·
4 2026-06-16 PRIMARY DOCUMENT view ·
4 2026-06-16 PRIMARY DOCUMENT view ·
4 2026-06-15 PRIMARY DOCUMENT view ·
4 2026-06-12 PRIMARY DOCUMENT view ·
4 2026-06-12 PRIMARY DOCUMENT view ·
4 2026-06-11 PRIMARY DOCUMENT view ·
4 2026-06-10 PRIMARY DOCUMENT view ·
4 2026-06-09 PRIMARY DOCUMENT view ·
4 2026-06-09 PRIMARY DOCUMENT view ·
4 2026-06-08 PRIMARY DOCUMENT view ·
4 2026-06-05 PRIMARY DOCUMENT view ·
4 2026-06-05 PRIMARY DOCUMENT view ·
4 2026-06-04 PRIMARY DOCUMENT view ·
4 2026-06-04 PRIMARY DOCUMENT view ·
4 2026-06-03 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-01 PRIMARY DOCUMENT view ·
4 2026-05-29 PRIMARY DOCUMENT view ·
4 2026-05-29 PRIMARY DOCUMENT view ·
4 2026-05-28 PRIMARY DOCUMENT view ·
4 2026-05-27 PRIMARY DOCUMENT view ·
4 2026-05-27 PRIMARY DOCUMENT view ·
4 2026-05-26 PRIMARY DOCUMENT view ·
4 2026-05-26 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·

About UTHR

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, incl…

Options picks · UTHR

ITM + OTM ideas from the latest scan

Loading…

Congress trades · UTHR

STOCK Act disclosures

Loading…

SEC filings & insiders · UTHR

EDGAR · live

Loading…

Holders · UTHR

Institutions & insider activity

Loading…